Jagsonpal Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Jagsonpal Pharmaceuticals has a total shareholder equity of ₹1.9B and total debt of ₹0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₹2.2B and ₹296.8M respectively. Jagsonpal Pharmaceuticals's EBIT is ₹214.0M making its interest coverage ratio 26.3. It has cash and short-term investments of ₹1.5B.
Key information
0%
Debt to equity ratio
₹0
Debt
Interest coverage ratio | 26.3x |
Cash | ₹1.48b |
Equity | ₹1.87b |
Total liabilities | ₹296.76m |
Total assets | ₹2.17b |
Recent financial health updates
No updates
Recent updates
There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings
May 27There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump
Apr 30A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Apr 05Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking
Feb 06Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Jul 29A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
May 13Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?
Jul 05A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Jun 13Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting
Apr 19Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?
Mar 21Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?
Feb 08The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio
Jan 08Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock
Dec 21Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 30Financial Position Analysis
Short Term Liabilities: JAGSNPHARM's short term assets (₹2.0B) exceed its short term liabilities (₹191.3M).
Long Term Liabilities: JAGSNPHARM's short term assets (₹2.0B) exceed its long term liabilities (₹105.5M).
Debt to Equity History and Analysis
Debt Level: JAGSNPHARM is debt free.
Reducing Debt: JAGSNPHARM has no debt compared to 5 years ago when its debt to equity ratio was 3.6%.
Debt Coverage: JAGSNPHARM has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: JAGSNPHARM has no debt, therefore coverage of interest payments is not a concern.